UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 565

Sortiert nach

Defensive Federalism: Protecting Territorial Minorities from the "Tyranny of the Majority"

1, 2023

Volltextzugriff (PDF)

The FTD‐like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism

The EMBO journal, 2017-07, Vol.36 (13), p.1837-1853

2017

Volltextzugriff (PDF)

Moralism in theories of secession: a realist perspective

Nations and nationalism, 2020-04, Vol.26 (2), p.323-343

Sanjaume‐Calvet, Marc

2020

Volltextzugriff (PDF)

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum

Brain (London, England : 1878), 2021-02, Vol.144 (1), p.325-339

2021

Volltextzugriff (PDF)

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation

EMBO molecular medicine, 2020-09, Vol.12 (9), p.e12308-n/a

2020

Volltextzugriff (PDF)

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

Molecular psychiatry, 2021-02, Vol.26 (2), p.429-442

2021

Volltextzugriff (PDF)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum

Alzheimer's & dementia, 2020-10, Vol.16 (10), p.1358-1371

2020

Volltextzugriff (PDF)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

EMBO molecular medicine, 2020-12, Vol.12 (12), p.e12921-n/a

2020

Volltextzugriff (PDF)

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

Acta neuropathologica, 2020-09, Vol.140 (3), p.267-278

2020

Volltextzugriff (PDF)

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury

Science translational medicine, 2016-12, Vol.8 (369), p.369ra178

2016

Volltextzugriff (PDF)

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease

EMBO molecular medicine, 2023-02, Vol.15 (2), p.e16987-n/a

2023

Volltextzugriff (PDF)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Nature medicine, 2022-09, Vol.28 (9), p.1797-1801

2022

Volltextzugriff (PDF)

Propagation of Tau Pathology in a Model of Early Alzheimer's Disease

Neuron (Cambridge, Mass.), 2012-02, Vol.73 (4), p.685-697

2012

Volltextzugriff (PDF)

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease

Science translational medicine, 2019-08, Vol.11 (507)

2019

Volltextzugriff (PDF)

CSF p-tau231: A biomarker for early preclinical Alzheimer?

EBioMedicine, 2022-03, Vol.77, p.103936-103936, Article 103936

Suárez-Calvet, Marc

2022

Volltextzugriff (PDF)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2021, Vol.13 (1), p.e12168-n/a

2021

Volltextzugriff (PDF)

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease

Brain (London, England : 1878), 2018-10, Vol.141 (10), p.3065-3080

2018

Volltextzugriff (PDF)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

EMBO molecular medicine, 2021-12, Vol.13 (12), p.e15098-n/a

2021

Volltextzugriff (PDF)

Associations between air pollution and biomarkers of Alzheimer’s disease in cognitively unimpaired individuals

Environment international, 2021-12, Vol.157, p.106864-106864, Article 106864

2021

Volltextzugriff (PDF)

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants

Human brain mapping, 2020-04, Vol.41 (5), p.1309-1322

2020

Volltextzugriff (PDF)

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease

Alzheimer's & dementia, 2016-12, Vol.12 (12), p.1259-1272

2016

Volltextzugriff (PDF)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

JAMA neurology, 2021-04, Vol.78 (4), p.396

2021

Volltextzugriff (PDF)

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Frontiers in neurology, 2019-03, Vol.10, p.280-280

2019

Volltextzugriff (PDF)

1 – 25 von 565

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(479)
Mit Volltextzugriff
(524)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Defensive Federalism: Protecting Territorial Minorities from the "Tyranny of the Majority"

The FTD‐like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism

Moralism in theories of secession: a realist perspective

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum

Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Propagation of Tau Pathology in a Model of Early Alzheimer's Disease

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease

CSF p-tau231: A biomarker for early preclinical Alzheimer?

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Associations between air pollution and biomarkers of Alzheimer’s disease in cognitively unimpaired individuals

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis

Suchergebnisse filtern